In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Fate Therapeutics Inc (NASDAQ: FATE) was $1.22 for the day, up 5.17% from the previous closing price of $1.16. In other words, the price has increased by $5.17 from its previous closing price. On the day, 1.4 million shares were traded.
Ratios:
Our analysis of FATE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.81 and its Current Ratio is at 8.81. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
On June 17, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $4 to $6.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 06 ’25 when Wolchko J Scott bought 113,178 shares for $0.93 per share.
Bressi Jerome Charles sold 5,980 shares of FATE for $9,269 on Jan 10 ’25. The insider now owns 270,203 shares after completing the transaction at $1.55 per share. On Jan 10 ’25, another insider, TAHL CINDY, who serves as the insider of the company, sold 5,654 shares for $1.55 each. As a result, the insider received 8,764 and left with 336,707 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 10.48 while its Price-to-Book (P/B) ratio in mrq is 0.48.
Stock Price History:
Over the past 52 weeks, FATE has reached a high of $5.92, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 17.05%, while the 200-Day Moving Average is calculated to be -40.69%.
Shares Statistics:
A total of 114.60M shares are outstanding, with a floating share count of 107.09M. Insiders hold about 6.58% of the company’s shares, while institutions hold 84.23% stake in the company.
